Three clinical trials in ccRCC patients (NCT02787915, NCT00197860, and NCT01924156) integrated the use of BIRC5 to assess survival or response to BIRC5-loaded dendritic cell vaccines. This evidence concerns the gene BIRC5 and nonpapillary renal cell carcinoma.